ArticleBiomedicines2026
Reconsidering Carotid Artery Stenting for Asymptomatic Carotid Stenosis in the Era of Endovascular Evolution.
Article in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management strategies in asymptomatic carotid artery stenosis are largely centered on intensive medical management, with carotid revascularization via endarterectomy or carotid artery stenting being reserved for select patients. This decision may be based on stenosis severity, perioperative risk, and patient preference. Current guidelines emphasize shared decision-making for patients with severe (>70%) stenosis, informed by prior trial data that does not demonstrate superiority of revascularization over independent medical therapy. Other studies more specifically recommend carotid endarterectomy over carotid artery stenting for asymptomatic patients with >60% stenosis. However, these studies are limited by poor statistical power. Recent findings in the CREST-2 trial have challenged this discussion of medical management as an independent primary course of action. The carotid artery stenting arm demonstrated significant long-term reduction in ipsilateral ischemic stroke compared to medical therapy alone. In this perspective, we argue that this new evidence supports a renewed role for carotid artery stenting in carefully selected patients with severe asymptomatic carotid artery stenting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.